reSET-O, the first PDT to receive Breakthrough Designation and authorized by FDA in December 2018, is an 84-day Prescription Digital Therapeutic (PDT) for Opioid Use Disorder (OUD) intended to increase retention of patients in outpatient treatment by providing cognitive behavioral therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.

Pear Therapeutics, Inc. is a venture-backed digital health company focused on the development of digital therapies and drug/software combinations to treat diseases with high unmet medical need.  PEAR's patented, clinically validated approach is designed to provide enhanced outcomes for patients, actionable data for clinicians, and cost-effective solutions for payers.

https://www.neuroflow.com/psychiatric-collaborative-care-model/

Psychiatric Collaborative Care (CoCM) is proven to be the most effective evidence-based integrated care model for behavioral health, enabling a holistic team-based approach to treating common mental health conditions by integrating behavioral health professionals into primary care. NeuroFlow’s tech-powered solution scales this highly effective model by offering a patient app experience and a cloud-based registry platform for patient management, which risk stratifies patients by severity level and connects virtual care team members for real-time collaboration. NeuroFlow also offers staffing for key behavioral health roles to support provider teams. 

NeuroFlow provides the technology infrastructure that leading healthcare organizations need to deliver effective and scalable integrated programs that improve access to behavioral healthcare and lower costs. Powered by proof and clinical expertise, NeuroFlow’s next generation software enables programs to bridge the gap between physical and mental health with proven solutions for psychiatric collaborative care, suicide prevention, and more. To learn more, visit http://www.neuroflow.com

For individuals with substance use disorder (SUD), reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention. Patients download the reSET app to their smartphone for secure, discreet, convenient access to therapy, interactive learning, and support.

• clinical decision support
• digital programming
• remote monitoring

• caseload reporting
• documentation compliance
• patient care tracking